Illinois Code § 410 ILCS 240/3.35

Spinal muscular atrophy.
Open in Lexace · Ask the AI about this section
In accordance with the timetable specified in this Section, the Department shall provide all newborns with a screening test for spinal muscular atrophy using a method that determines the presence or absence of the intact or normal SMN1 gene, beginning on the earlier of the following:
 
 
(1) July 1, 2020; or
 
 
(2) within 6 months following the occurrence of all 
 
of the following:
 
 
 
(A) the establishment and verification of 
 
 
relevant and appropriate performance specifications as defined under the federal Clinical Laboratory Improvement Amendments and regulations thereunder for federal Food and Drug Administration-cleared or in-house developed methods, performed under an institutional review board approved protocol, if required;
 
 
 
(B) the availability of quality assurance 
 
 
materials and comparative threshold values to determine the presence or absence of the intact or normal SMN1 gene;
 
 
 
(C) the procurement and installation by the 
 
 
Department of the equipment necessary to implement the initial pilot and statewide volume of screening tests for spinal muscular atrophy;
 
 
 
(D) the establishment of precise threshold values 
 
 
ensuring defined disorder identification for spinal muscular atrophy;
 
 
 
(E) the development and validation of a reliable 
 
 
methodology for screening newborns for spinal muscular atrophy using dried blood spots and quality assurance testing methodology for such test or the approval and procurement of a test for spinal muscular atrophy using dried blood spots by the federal Food and Drug Administration; 
 
 
 
(F) the authentication of pilot testing achieving 
 
 
each milestone described in subparagraphs (A) through (E) of this paragraph for spinal muscular atrophy; and
 
 
 
(G) the authentication of achieving the potential 
 
 
of high throughput standards for statewide volume of spinal muscular atrophy concomitant with each milestone described in subparagraphs (A) through (E) of this paragraph.
 
The Department is authorized to implement an additional fee for the screening upon the effective date of this amendatory Act of the 100th General Assembly in order to accumulate the resources for start-up and other costs associated with the implementation of the screening and thereafter to support the costs associated with screening. If the Department has not implemented statewide screening for spinal muscular atrophy under this Section within 36 months after the effective date of this amendatory Act of the 100th General Assembly, then the Department shall cease collecting any additional fees related to the screening. The Department may adopt emergency rules in accordance with Section 5-45 of the Illinois Administrative Procedure Act to implement this Section.

of the following:
relevant and appropriate performance specifications as defined under the federal Clinical Laboratory Improvement Amendments and regulations thereunder for federal Food and Drug Administration-cleared or in-house developed methods, performed under an institutional review board approved protocol, if required;
materials and comparative threshold values to determine the presence or absence of the intact or normal SMN1 gene;
Department of the equipment necessary to implement the initial pilot and statewide volume of screening tests for spinal muscular atrophy;
ensuring defined disorder identification for spinal muscular atrophy;
methodology for screening newborns for spinal muscular atrophy using dried blood spots and quality assurance testing methodology for such test or the approval and procurement of a test for spinal muscular atrophy using dried blood spots by the federal Food and Drug Administration;
each milestone described in subparagraphs (A) through (E) of this paragraph for spinal muscular atrophy; and
of high throughput standards for statewide volume of spinal muscular atrophy concomitant with each milestone described in subparagraphs (A) through (E) of this paragraph.

‹ Prev All Illinois sections Next ›


Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.